Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1
Biotech
Ottimo raises $140M to ready PD1/VEGFR2 antibody for clinic
Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured $140 million in series A funds.
James Waldron
Dec 19, 2024 6:58am
HanxBio plans Hong Kong IPO to fund phase 2 solid tumor trial
Nov 25, 2024 9:20am
Engineered yeast delivers PD-1 inhibitors, shrinks mice tumors
Nov 22, 2024 3:12pm
Former Seagen CEO unveils new startup Ottimo Pharma
Oct 28, 2024 11:24am
Boehringer pays OSE $42M to grab new asset, expand into cardio
May 22, 2024 4:47am
New immunotherapy drug design ups survival in mice with cancer
Apr 23, 2024 3:40am
